therapeutic agents (Twentyman & Bleehen 1973b) and found that our results are the opposite of those recently reported by Barranco et al. (1973) and those mentioned by Dr Frei (1974) . Thus they found that BLM was more active against plateau phase cells. However, our results with a different mammalian cell line (EMT6/CC) show the opposite effect, with plateau phase cells less sensitive than log phase cells. Barranco et al. (1973) also reported the same type of effect with BCNU. Our results show a similar trend, but with nowhere near the same quantitative advantage. These dissimilarities may possibly be explained by differences between the kinetic parameters of the two models (Twentyman & Bleehen 1973b) but one is led to question the value of extrapolating results from such a model to man.
These are some results for single agents. When one looks at a combination of agents the situation is likely to become even more complex. I wish to quote one more example from our own work. Bleomycin is normally regarded as being nontoxic to the bone marrow and in the mouse one can confirm this using the spleen colony technique. As a single chemotherapeutic agent it is rather disappointing in clinical practice. For this reason it is being used increasingly clinically in combination with other drugs, on the basis that it may add some antitumour effect and will not be harmful to the marrow. However, it may be just in this situation, where another chemotherapeutic agent has damaged the marrow and caused stem cell proliferation, that BLM might cause permanent stem cell killing. We have demonstrated such an effect of BLM on the marrow from mice which have been treated with endotoxin one hour earlier in order to produce stem cell proliferation (Twentyman & Bleehen 1973a However, at present the experimental chemotherapist can only take the drugs known to be effective in the treatment of a malignancy and show that a certain combination is the most advantageous and that no antagonism occurs between the various components.
Combination chemotherapy was developed on the rationale that chemicals that were effective anti-cancer agents but had different limiting toxicity could be used in association without reduction in the maximum tolerated dose levels employed. In this situation the tumour cell kill is likely to be additive but the toxicity is not and thus 'therapeutic synergism' occurs (Venditti & Goldin 1964) . This hypothesis has been substantiated in laboratory animals. Table 1 shows some of the agents which have proved effective in the treatment of acute lymphoblastic leuktmia in children and their major side effects. Two agents which have the same limiting toxicity, methoSection ofOncology trexate and 6-mercaptopurine, are additive in their toxicity to mice since a combination of the dose level of each that causes 10% toxicity, results in an 80% mortality rate (Henderson 1968) . In man, each drug in the combination would have to be reduced by about 40% of the single drug level and little advantage would be gained. However, where the major side effects are quite different such as in the case ofprednisone and 6-mercaptopurine there is no addition in toxicity and the LD10 values of the individual drugs remain the same in combination, and consequently in man there is no need to reduce the amounts administered. In this way, combinations offour or more drugs have been built up, and it is quite clear from controlled clinical trials, that for some cancers the extension of tumour free survival time that has been obtained by combinations has been far greater than would have been expected from individual drug therapy.
The situation, however, is more complicated than this because of the existence of true synergism or antagonism between various anticancer agents. Table 2 shows that in experiments on the L1210 leukaemia there is no advantage in using combinations of cis-dichlorodiammineplatinum II and 1, 3 bis (2-chlorcethyl)-1-nitrosourea (BCNU) since both compounds have similar side effects and, as expected, show no therapeutic synergism (Woodman et al. 1973 ). However, the alkylating agent isophosphamide is also quite similar to the platinum compound in its side effects and can only be given in a reduced amount in combination. Nevertheless there is an advantage because cures are obtained in the combination treatment but not with the agents used singly. This is similar to clinical reports that combinations of the two alkylating agents, cyclophosphamide and melphalan are superior in the treatment of myeloma, than either drug alone, a finding that cannot be explained in terms of our current day knowledge, since all alkylating agents act by a basically similar mechanism. A recent observation has been that the anti-tumour agent ICRF 159, in combination with daunomycin, is highly effective because the former, while maintaining its anti-tumour properties, reduces the LD50 of the latter so that much larger quantities can be given (Woodman et al. 1972 ).
There are many such examples of drug addition and synergism but it has also been demonstrated that some drugs may be antagonistic to one another. One example is of the antagonism of the anti-tumour action of asparaginase by methotrexate (Connors & Jones 1970) . Both compounds significantly extend the survival time of mice injected with the RI lymphoma (Table 3) . However, if both are administered simultaneously, the combination is only as effective as the methotrexate it contains, although when administered sequentially the drugs are additive. Asparaginase can completely abolish the anti-tumour effects of methotrexate in other animal tumours and in patients with leukeemia sensitive to the enzyme (Capizzi et al. 1970) . It seems that the protein inhibitory action of asparaginase prevents nucleic acid synthesis and thus protects the tumour from methotrexate which is essentially a phase specific agent. It is likely that the whole animal is also protected and that there is a reduction in toxicity, but unless the possibility of antagonism between the two drugs is realized by the clinician, suboptimal drug concentrations may be administered. A similar antagonism has also been observed between cytosine arabinoside and asparaginase and it may well be that the inhibition of protein synthesis caused by the enzyme may protect tumour cells against all phase specific agents.
A strong antagonism also occurs between methotrexate and cytosine arabinoside (Table 4) but once again an important element of timing is involved. Both anti-metabolites, at their optimal doses, extend the survival time of mice with the TLX5 lymphoma. If the two compounds are administered simultaneously or the cytosine arabinoside is given six hours before the methotrexate, there is a good additive anti-tumour effect. When the methotrexate is given six hours before the cytosine arabinoside, however, there is a mutual antagonism of the anti-tumour effects with no reduction in whole animal toxicity (Tattersall et al. 1972) . In this case the high intracellular level of deoxycytidine tri- (Mihich 1969 , Schmid & Hutchison 1972 , Nicolin et al. 1973 , Tsukagoshi & Hashimoto 1973 . The TLX5 lymphoma, for instance, with acquired resistance to BCNU, is cross-resistant to triazenes such as DIC, which probably act by a similar mechanism, but is more sensitive than the parent line to anti-metabolites such as methotrexate or cytosine arabinoside (Connors 1973) . In extreme cases, tumours may be very sensitive to particular agents whereas the parent line from which they are derived show no response at all (Tsukagoshi & Hashimoto 1973) . The acquisition of resistance often involves the loss of an enzyme or its induction in abnormal quantities, and it is these biochemical changes that may be responsible for collateral sensitivity. It has been suggested that use may be made of these changes in the design of logical drug combinations. Many cell types for instance acquire resistance to methotrexate by the induction of high levels of folate reductase enzymes. These enzymes activate the anti-metabolite homofolates and it has been suggested that they should be used after treatment with methotrexate (Tattersall 1973) . 5-Fluorocytosine is inactive in man and non-toxic and is used as an anti-fungal agent. In patients with acute myeloid leukemia treated by infusions ofcytosine arabinoside, resistance can arise by induction or selection or tumour cells with high levels of the enzyme cytidine deaminase (Steuart & Burke 1971) , which converts the antimetabolite to the inactive uracil arabinoside. However, the same enzyme can convert 5-fluorocytosine (Fig 1) to 5-fluorouracil, an active anti-tumour agent (in the form of its deoxyribotide). Therefore, in patients with acute myeloid leukaemia and with acquired resistance to cytosine arabinoside, there may be a selective activation of 5-fluorocytosine in tumour cells to a cytotoxic derivative. It has been suggested that a logical combination in the treatment of this malignancy would be a course of 5-fluorocytosine following an infusion of cytosine arabinoside, especially if there was evidence of an increased level of cytidine deaminase in the bone marrow (Tattersall 1973) .
It seems for the time being that more effective drug combinations will be developed by the clinician on a trial and error basis. However, as knowledge of the effects of cytotoxic agents on tumour cells increases, it may be possible in the future to design effective drug combinations on a logical basis.
